{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:58:49Z","timestamp":1791575929775,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00125-021-05529-w","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T04:02:21Z","timestamp":1631937741000},"page":"2676-2686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials"],"prefix":"10.1007","volume":"64","author":[{"given":"Donna Shu-Han","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Kuang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Sheng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"issue":"9995","key":"5529_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","unstructured":"Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386(9995):743\u2013800. https:\/\/doi.org\/10.1016\/S0140-6736(15)60692-4","journal-title":"Lancet"},{"issue":"13","key":"5529_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","volume":"119","author":"SR Preis","year":"2009","unstructured":"Preis SR, Hwang S-J, Coady S et al (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 119(13):1728\u20131735. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.829176","journal-title":"Circulation."},{"issue":"9","key":"5529_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"S Rao Kondapally Seshasai","year":"2011","unstructured":"Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa1008862","journal-title":"N Engl J Med"},{"issue":"9","key":"5529_CR4","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ et al (2020) Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 141(9):e139\u2013e596. https:\/\/doi.org\/10.1161\/CIR.0000000000000757","journal-title":"Circulation."},{"issue":"14","key":"5529_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMp1309610","volume":"369","author":"WR Hiatt","year":"2013","unstructured":"Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. N Engl J Med 369(14):1285\u20131287. https:\/\/doi.org\/10.1056\/NEJMp1309610","journal-title":"N Engl J Med"},{"issue":"16","key":"5529_CR6","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","volume":"75","author":"T Wilcox","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD (2020) Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC Focus Seminar. J Am Coll Cardiol 75(16):1956\u20131974. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.056","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"5529_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"5529_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"5529_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"15","key":"5529_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"issue":"4","key":"5529_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"19","key":"5529_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"9","key":"5529_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"issue":"10193","key":"5529_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet."},{"issue":"10157","key":"5529_CR15","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 392(10157):1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet."},{"issue":"23","key":"5529_CR16","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"issue":"1","key":"5529_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503919","volume":"10","author":"KB Lo","year":"2020","unstructured":"Lo KB, Gul F, Ram P et al (2020) The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med 10(1):1\u201310. https:\/\/doi.org\/10.1159\/000503919","journal-title":"Cardiorenal Med"},{"issue":"17","key":"5529_CR18","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 139(17):2022\u20132031. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation."},{"issue":"1","key":"5529_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","volume":"18","author":"Y Fei","year":"2019","unstructured":"Fei Y, Tsoi M-F, Cheung BMY (2019) Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol 18(1):112. https:\/\/doi.org\/10.1186\/s12933-019-0916-z","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"5529_CR20","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"21","key":"5529_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"15","key":"5529_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"5529_CR23","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Szarek M, Pitt B et al (2020) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2030186","DOI":"10.1056\/NEJMoa2030186"},{"key":"5529_CR24","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2020) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2030183","DOI":"10.1056\/NEJMoa2030183"},{"issue":"4","key":"5529_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","volume":"10","author":"T Gaspari","year":"2013","unstructured":"Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE (2013) The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model. Diab Vasc Dis Res 10(4):353\u2013360. https:\/\/doi.org\/10.1177\/1479164113481817","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"5529_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2012.11.009","volume":"100","author":"S Herzlinger","year":"2013","unstructured":"Herzlinger S, Horton ES (2013) Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabetes Res Clin Pract 100(1):1\u201310. https:\/\/doi.org\/10.1016\/j.diabres.2012.11.009","journal-title":"Diabetes Res Clin Pract"},{"key":"5529_CR27","doi-asserted-by":"publisher","first-page":"154343","DOI":"10.1016\/j.metabol.2020.154343","volume":"111","author":"A Sachinidis","year":"2020","unstructured":"Sachinidis A, Nikolic D, Stoian AP et al (2020) Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metab Clin Exp 111:154343. https:\/\/doi.org\/10.1016\/j.metabol.2020.154343","journal-title":"Metab Clin Exp"},{"key":"5529_CR28","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jacc.2018.07.071","volume":"72","author":"JD Newman","year":"2018","unstructured":"Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ (2018) The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC State-of-the-Art Review. J Am Coll Cardiol 72:1856\u20131869","journal-title":"J Am Coll Cardiol"},{"key":"5529_CR29","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ (2017) Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136:1643\u20131658. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030012","journal-title":"Circulation"},{"issue":"4","key":"5529_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173(4):278\u2013286. https:\/\/doi.org\/10.7326\/M20-0864","journal-title":"Ann Intern Med"},{"issue":"3","key":"5529_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/1573403x11666141122220003","volume":"11","author":"G Graham","year":"2015","unstructured":"Graham G (2015) Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev 11(3):238\u2013245. https:\/\/doi.org\/10.2174\/1573403x11666141122220003","journal-title":"Curr Cardiol Rev"},{"issue":"5","key":"5529_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/clc.22524","volume":"39","author":"G Graham","year":"2016","unstructured":"Graham G (2016) Racial and ethnic differences in acute coronary syndrome and myocardial infarction within the United States: from demographics to outcomes. Clin Cardiol 39(5):299\u2013306. https:\/\/doi.org\/10.1002\/clc.22524","journal-title":"Clin Cardiol"},{"issue":"3","key":"5529_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MOL.0000000000000412","volume":"28","author":"K Gazzola","year":"2017","unstructured":"Gazzola K, Reeskamp L, van den Born B-J (2017) Ethnicity, lipids and cardiovascular disease. Curr Opin Lipidol 28(3):225\u2013230. https:\/\/doi.org\/10.1097\/MOL.0000000000000412","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"5529_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000000580","volume":"138","author":"AS Volgman","year":"2018","unstructured":"Volgman AS, Palaniappan LS, Aggarwal NT et al (2018) Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 138(1):e1\u2013e34. https:\/\/doi.org\/10.1161\/CIR.0000000000000580","journal-title":"Circulation."},{"issue":"4","key":"5529_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/HCO.0000000000000411","volume":"32","author":"A Jain","year":"2017","unstructured":"Jain A, Puri R, Nair DR (2017) South Asians: why are they at a higher risk for cardiovascular disease? Curr Opin Cardiol 32(4):430\u2013436. https:\/\/doi.org\/10.1097\/HCO.0000000000000411","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"5529_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159(2):130\u2013137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","journal-title":"Ann Intern Med"},{"key":"5529_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-40105-4","volume-title":"Design and analysis of subgroups with biopharmaceutical applications","author":"N Ting","year":"2020","unstructured":"Ting N, Cappelleri JC, Ho S (2020) Design and analysis of subgroups with biopharmaceutical applications. Springer, New York"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05529-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-021-05529-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05529-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T00:02:40Z","timestamp":1663459360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-021-05529-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5529"],"URL":"https:\/\/doi.org\/10.1007\/s00125-021-05529-w","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,18]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}